IMMUNITYBIO INC (IBRX) Fundamental Analysis & Valuation

NASDAQ:IBRX • US45256X1037

Current stock price

8.47 USD
-0.35 (-3.97%)
At close:
8.54 USD
+0.07 (+0.83%)
After Hours:

This IBRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IBRX Profitability Analysis

1.1 Basic Checks

  • In the past year IBRX has reported negative net income.
  • In the past year IBRX has reported a negative cash flow from operations.
  • In the past 5 years IBRX always reported negative net income.
  • In the past 5 years IBRX always reported negative operating cash flow.
IBRX Yearly Net Income VS EBIT VS OCF VS FCFIBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M -500M

1.2 Ratios

  • IBRX has a Return On Assets of -70.01%. This is in the lower half of the industry: IBRX underperforms 62.48% of its industry peers.
Industry RankSector Rank
ROA -70.01%
ROE N/A
ROIC N/A
ROA(3y)-97.87%
ROA(5y)-96.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBRX Yearly ROA, ROE, ROICIBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100

1.3 Margins

  • IBRX's Gross Margin of 99.34% is amongst the best of the industry. IBRX outperforms 98.45% of its industry peers.
  • IBRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBRX Yearly Profit, Operating, Gross MarginsIBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100K -200K -300K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. IBRX Health Analysis

2.1 Basic Checks

  • IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IBRX has more shares outstanding
  • IBRX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, IBRX has an improved debt to assets ratio.
IBRX Yearly Shares OutstandingIBRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
IBRX Yearly Total Debt VS Total AssetsIBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • IBRX has an Altman-Z score of -5.82. This is a bad value and indicates that IBRX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -5.82, IBRX is not doing good in the industry: 64.99% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.82
ROIC/WACCN/A
WACC8.89%
IBRX Yearly LT Debt VS Equity VS FCFIBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M

2.3 Liquidity

  • IBRX has a Current Ratio of 5.10. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
  • IBRX has a Current ratio (5.10) which is in line with its industry peers.
  • A Quick Ratio of 5.08 indicates that IBRX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.08, IBRX is in line with its industry, outperforming 58.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.1
Quick Ratio 5.08
IBRX Yearly Current Assets VS Current LiabilitesIBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. IBRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 37.70% over the past year.
  • IBRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 668.31%.
  • Measured over the past years, IBRX shows a very strong growth in Revenue. The Revenue has been growing by 184.30% on average per year.
EPS 1Y (TTM)37.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)668.31%
Revenue growth 3Y678.62%
Revenue growth 5Y184.3%
Sales Q2Q%406.95%

3.2 Future

  • Based on estimates for the next years, IBRX will show a very strong growth in Earnings Per Share. The EPS will grow by 52.97% on average per year.
  • IBRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 100.38% yearly.
EPS Next Y20.01%
EPS Next 2Y34.86%
EPS Next 3Y46.93%
EPS Next 5Y52.97%
Revenue Next Year85.73%
Revenue Next 2Y114.18%
Revenue Next 3Y119.18%
Revenue Next 5Y100.38%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IBRX Yearly Revenue VS EstimatesIBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
IBRX Yearly EPS VS EstimatesIBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. IBRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IBRX. In the last year negative earnings were reported.
  • Also next year IBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBRX Price Earnings VS Forward Price EarningsIBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBRX Per share dataIBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • IBRX's earnings are expected to grow with 46.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.86%
EPS Next 3Y46.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IBRX Dividend Analysis

5.1 Amount

  • No dividends for IBRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBRX Fundamentals: All Metrics, Ratios and Statistics

IMMUNITYBIO INC

NASDAQ:IBRX (3/20/2026, 8:00:20 PM)

After market: 8.54 +0.07 (+0.83%)

8.47

-0.35 (-3.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-23
Earnings (Next)05-11
Inst Owners16.86%
Inst Owner Change13.43%
Ins Owners3.31%
Ins Owner Change0.37%
Market Cap8.71B
Revenue(TTM)113.29M
Net Income(TTM)-351.40M
Analysts85.45
Price Target13.06 (54.19%)
Short Float %35.44%
Short Ratio3.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.94%
Min EPS beat(2)36.46%
Max EPS beat(2)37.42%
EPS beat(4)3
Avg EPS beat(4)17.47%
Min EPS beat(4)-14.89%
Max EPS beat(4)37.42%
EPS beat(8)5
Avg EPS beat(8)15.31%
EPS beat(12)7
Avg EPS beat(12)2.27%
EPS beat(16)8
Avg EPS beat(16)-1.64%
Revenue beat(2)1
Avg Revenue beat(2)-0.01%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)1.39%
Revenue beat(4)3
Avg Revenue beat(4)3.72%
Min Revenue beat(4)-1.41%
Max Revenue beat(4)13.79%
Revenue beat(8)5
Avg Revenue beat(8)13.97%
Revenue beat(12)9
Avg Revenue beat(12)179.25%
Revenue beat(16)12
Avg Revenue beat(16)168.26%
PT rev (1m)8.47%
PT rev (3m)25.49%
EPS NQ rev (1m)6.25%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)-3.47%
EPS NY rev (3m)9.7%
Revenue NQ rev (1m)9.01%
Revenue NQ rev (3m)9.01%
Revenue NY rev (1m)-2.42%
Revenue NY rev (3m)0.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 76.87
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.11
BVpS-0.49
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.34%
FCFM N/A
ROA(3y)-97.87%
ROA(5y)-96.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.39%
Cap/Sales 3.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.1
Quick Ratio 5.08
Altman-Z -5.82
F-Score5
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)77.28%
Cap/Depr(5y)202.36%
Cap/Sales(3y)1655.84%
Cap/Sales(5y)9997.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y20.01%
EPS Next 2Y34.86%
EPS Next 3Y46.93%
EPS Next 5Y52.97%
Revenue 1Y (TTM)668.31%
Revenue growth 3Y678.62%
Revenue growth 5Y184.3%
Sales Q2Q%406.95%
Revenue Next Year85.73%
Revenue Next 2Y114.18%
Revenue Next 3Y119.18%
Revenue Next 5Y100.38%
EBIT growth 1Y25.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.06%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNITYBIO INC / IBRX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IMMUNITYBIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to IBRX.


What is the valuation status of IMMUNITYBIO INC (IBRX) stock?

ChartMill assigns a valuation rating of 1 / 10 to IMMUNITYBIO INC (IBRX). This can be considered as Overvalued.


What is the profitability of IBRX stock?

IMMUNITYBIO INC (IBRX) has a profitability rating of 1 / 10.


What is the financial health of IMMUNITYBIO INC (IBRX) stock?

The financial health rating of IMMUNITYBIO INC (IBRX) is 3 / 10.